Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 30 2025
0mins
Source: Newsfilter
Patent Grant Announcement: Protagenic Therapeutics, Inc. has received a patent from the Japanese Patent Office for a modified stilbenoid aimed at treating epilepsy and seizures, which will provide exclusivity until March 31, 2041.
Market Insights: The Japanese pharmaceutical market is projected to grow from over $85 billion in 2025 to $93 billion by 2030, while the global epilepsy drug market is expected to increase from $11.29 billion in 2024 to around $18.74 billion by 2034.
Analyst Views on PTIX
About PTIX
Protagenic Therapeutics, Inc. is a neuroactive biopharmaceutical company. The Company has approximately six drug candidates targeting stress-related and CNS disorders, including treatments for obesity and metabolic disorders. The Company's pipeline includes PT-00114 in Phase I/IIa and five preclinical assets including PHYX-001, cannabinoid-based compounds, and modified stilbenoid assets. The PHYX-001 is a potassium channel modulator with a mechanism similar to XEN1101 and BHV-7000. The Company's cannabinoid assets include multiple cannabinoid-based compounds with composition-of-matter IP; potential in CNS, cardiometabolic, and other indications. The Company's cannabinoid assets also include a molecule with potential in the obesity, metabolic dysfunction sector, where the GLP-1 agonists have become medications. Its modified stilbenoid assets include modified stilbenoid compounds with composition-of-matter IP and anticonvulsant activity in preclinical models.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
